secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001213900-21-059489
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics appoints Diana M. Brainard, M.D. to board of directors
--------------------------------------------------------------------------

- Dr. Brainard appointed as Class III Director effective Nov 11, 2021; term expires at 2022 annual meeting.
- Board determined she is independent under SEC and Nasdaq rules.
- She receives standard non-employee director compensation: initial option for 36,720 shares vesting over 3 years, RSU for 18,360 shares vesting over 3 years, and $65,000 annual cash retainer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390021059489/0001213900-21-059489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390021059489/ea150696-8k_nektartherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-059489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer